Practical Guidance continues to expand its collection of workflow-focused legal resources with the March 2026 update. This release introduces new templates, trackers, practice notes, and jurisdiction-specific...
How AI legal issues are being addressed with practical guidance The new generation of AI-related legal issues are inherently cross-disciplinary, implicating corporate law, intellectual property, data...
Legal teams continue to face increased pressure to manage evolving regulatory requirements, shifting case law, and growing client expectations. The February 2026 update to Practical Guidance reflects these...
Summary of Sections Real Market Data in Enhanced M&A Templates at Your Fingertips Addressing the Competitive Landscape Rollout Conclusion M&A practitioners know that drafting...
LexisNexis® Practical Guidance continues to empower legal professionals with fresh, actionable insights and resources. The July 2025 update delivers a wide range of new legal tools, regulatory trackers...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
The most robust due diligence disclosures are keyed to the company’s industry, stage of growth, and other particular circumstances. Pharmaceutical companies operate in a highly-regulated space, while development-stage companies in that industry face high costs of entry and often a lack of familiarity with the details of the approval process for their products. Use this template as a basis for getting the information you need from management to make all appropriate disclosures in the offering documents.
READ NOW »
Related Content
Practical Guidance Updates Featuring the latest updates from your Practical Guidance account.
PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.Experience Lexis+